VC fund profile · evidence-aware directory data
Advent Life Sciences stages, portfolio and investment profile
London-based transatlantic specialist life-sciences venture and growth investor. British Business Bank separately announced September 2026 commitments to its early-stage Fund IV and Growth Fund. These were LP commitments, not announced completed fund closes. The manager also co-led T-Therapeutics' $133M Series B in November 2026.
Keep track of Advent Life Sciences
Save this profile to your VCT watchlist for a quick return.
Stage-based planning range
$1M–$10M
This is a planning range inferred from stage coverage, not a firm-disclosed check size.
Methodology: Stage bucket inferred from the rounds a fund leads or invests in.
No firm-specific check-size disclosure is recorded.
Investment stages
Leads: Not recorded
Participates: Seed, Series A, Series B, Series C, Growth
Sector focus
Not recorded
Geography
London, UK
Founded Not recorded
Fund size / AUM
Not recorded
A separate fund-size evidence record is not yet available.
Portfolio in our directory
None yet
Linked startup profiles
Recent tracked investment
Not recorded
No dated round explicitly links this fund.
VCT investor research
Inside Advent Life Sciences's investment strategy
Independent, source-backed analysis of who the firm backs, deal evidence and whether it fits your stage.
Investment strategy
Advent Life Sciences backs medicines, medtech and life-sciences platform companies in the UK, Europe and US. It is distinct from Advent International, the buyout investor.
Fund history and 2026 vehicle distinction
British Business Bank reports earlier backing of the 2019-vintage Advent Life Sciences Fund III, followed by two distinct vehicles: Fund IV, targeting early-stage development, and Advent Life Sciences Growth Fund, backing clinical progress and nontherapeutic commercial scale-up. September 2026 bank allocations of about €69.8M agreed to Fund IV and €87.2M committed to Growth Fund are one LP's allocations, not each fund's total capital or a legal closing event.
Founder fit and diligence
Early biotech teams should demonstrate target validation, patents and runway to next clinical decision. A growth-stage company should provide trial milestones or repeatable commercial economics, with realistic regulatory and market access assumptions. These are illustrative requirements aligned with published mandates, not claimed official eligibility checklists. No universal fund-specific cheque size, carry or management fee has been verified.
Reported portfolio context
The LP includes KaNDy Therapeutics, Nalu Medical, Miro Therapeutics, Levicept, Axonics and Cyted Health among historical manager investments, not verified Fund IV/Growth holdings. Advent separately co-led T-Therapeutics' $133M November 2026 Series B; portfolio funding is not GP fundraising.
Sources: Bank commitment announcement, Fund IV listing, Growth Fund listing.
Sources and verification
Dated company disclosures take priority over third-party databases. These sources support the analysis above.
Rounds they lead
Rounds they invest
Last verified: Not recorded. Check-size evidence is labeled by basis so planning estimates are not presented as firm disclosures.
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.